Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion
- Conditions
- Inappropriate ADH SyndromeHyponatremia
- First Posted Date
- 2005-12-13
- Last Posted Date
- 2008-12-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 77
- Registration Number
- NCT00264927
- Locations
- 🇪🇸
Sanofi-Aventis Administrative Office, Barcelona, Spain
AMISH : Aprovel for Management of Isolated Systolic Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2005-12-12
- Last Posted Date
- 2007-12-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 436
- Registration Number
- NCT00264212
- Locations
- 🇹🇭
Sanofi-Aventis, Bangkok, Thailand
VALID : VAlproate Versus LIthium in Bipolar Disorders
- Conditions
- Bipolar Disorder
- First Posted Date
- 2005-12-12
- Last Posted Date
- 2007-11-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 270
- Registration Number
- NCT00264173
Oxaliplatin in Gastric Cancer
- Conditions
- Stomach Neoplasms
- First Posted Date
- 2005-12-08
- Last Posted Date
- 2010-11-09
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 20
- Registration Number
- NCT00263354
Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes
- Conditions
- Cardiovascular Disease
- Interventions
- Drug: Placebo (for Rimonabant)
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2016-05-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 18695
- Registration Number
- NCT00263042
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford, United Kingdom
🇦🇺sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, New South Wales, Australia
Preoperative Radiotherapy/ Oxaliplatin/ Capecitabine Treatment For Unresectable Locally-advanced Rectal Cancer
- Conditions
- Rectal Neoplasms
- Interventions
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2009-09-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 18
- Registration Number
- NCT00263029
MASCOT : Multicenter Asia Study in Adjuvant Treatment of Colon Cancer With OxaliplaTin/5FU-LV
- Conditions
- Colonic Neoplasms
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2009-09-15
- Lead Sponsor
- Sanofi
- Registration Number
- NCT00263055
- Locations
- 🇰🇷
Sanofi-aventis, Seoul, Korea, Republic of
🇹🇭Sanofi-Aventis, Bangkok, Thailand
Irbesartan/Hydrochlorothiazide and Irbesartan in the Treatment of Mild to Moderate Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2007-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 40
- Registration Number
- NCT00263003
- Locations
- 🇨🇳
Sanofi-Aventis, Taipei, Taiwan
Docetaxel in Non Small Cell Lung Cancer (NSCLC)
- Conditions
- Carcinoma, Non-Small-Cell Lung
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2008-03-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 50
- Registration Number
- NCT00263016
- Locations
- 🇭🇰
Sanofi-aventis, Hong Kong, Hong Kong
Docetaxel in Head and Neck Cancer
- Conditions
- Head and Neck Neoplasms
- Interventions
- Other: Cisplatin + radiotherapy
- First Posted Date
- 2005-12-05
- Last Posted Date
- 2012-05-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 439
- Registration Number
- NCT00261703
- Locations
- 🇪🇸
Sanofi-Aventis, Barcelona, Spain